Investigating blood glucose variability in type 2 diabetes patients with COVID-19
Characteristics of Blood Glucose Variability in Patients With Type 2 Diabetes Mellitus Complicated With COVID-19 and Its Effect on the Prognosis of the Disease
This study is testing how blood sugar levels change in people with type 2 diabetes who have COVID-19 to see if understanding these changes can help improve their treatment and recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Qilu Hospital of Shandong University Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06156137 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze blood glucose variability in patients with type 2 diabetes mellitus (T2DM) who are also suffering from COVID-19 pneumonia. By utilizing intermittently scanned continuous glucose monitoring (isCGM), the study will collect clinical data and various glucose variability parameters to understand their impact on disease progression and patient prognosis. The goal is to identify a clinically practical time-in-range (TIR) threshold that can guide treatment adjustments, ultimately improving patient outcomes and reducing hospital stays and medical costs.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with type 2 diabetes mellitus who are currently hospitalized with mild to critical COVID-19 pneumonia.
Not a fit: Patients who do not have type 2 diabetes or COVID-19 pneumonia will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for T2DM patients with COVID-19, enhancing their recovery and overall health outcomes.
How similar studies have performed: While studies on glucose variability in diabetes are common, this specific focus on T2DM patients with COVID-19 pneumonia is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. All patients met the diagnostic criteria of type 2 diabetes mellitus in "Chinese Guidelines for the Prevention and treatment of type 2 Diabetes Mellitus (2020 edition)" formulated by the Chinese Diabetes Society of the Chinese Medical Association, and were previously diagnosed with type 2 diabetes mellitus and newly diagnosed with type 2 diabetes mellitus after admission 2. Patients with mild, moderate, severe and critical COVID-19 in accordance with the guidelines of "Diagnosis and Treatment of novel coronavirus Infection (Trial version 10)" 3. Patients receiving CGM or peripheral blood glucose monitoring during hospitalization Exclusion Criteria: 1. Cases with incomplete data 2. Non-NCP and non-T2DM patients 3. Patients who did not receive CGM or peripheral blood glucose monitoring
Where this trial is running
Jinan, Shandong
- Qilu hospital of shandong university — Jinan, Shandong, China (Recruiting)
Study contacts
- Principal investigator: Kuanxiao Tang, M.D. — Qilu Hospital of Shandong University
- Study coordinator: Kuanxiao Tang, M.D.
- Email: tangkx_ql@hotmail.com
- Phone: 18560082261
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.